PURPOSE: To investigate whether caffeine, which transiently increases intraocular pressure (IOP) is associated with the risk of primary open-angle glaucoma (POAG). METHODS: A total of 79,120 women from 1980 to 2004 and 42,052 men from 1986 to 2004, who were 40+ years of age, did not have POAG, and reported undergoing eye examinations, were observed. Information on caffeine consumption, potential confounders, and POAG diagnoses were repeatedly updated in validated follow-up questionnaires. One thousand eleven incident POAG cases were confirmed with medical record review. Cohort-specific and pooled analyses across cohorts were conducted to calculate multivariate rate ratios (RRs). RESULTS: Compared with daily intake of less than 150 mg, the pooled multivariate RRs were 1.05 (95% confidence interval [CI], 0.89-1.25) for consumption of 150 to 299 mg/d, 1.19 (95% CI, 0.99-1.43) for 300 to 449 mg/d, 1.13 (95% CI, 0.89-1.43) for 450 to 559 mg/d, and 1.17 (95% CI, 0.90-1.53) for 600+ mg/d (P for trend = 0.11). However, for consumption of five or more cups of caffeinated coffee daily, the RR was 1.61 (95% CI, 1.00-2.59; P for trend = 0.02); tea or caffeinated cola intake were not associated with risk. Greater caffeine intake was more adversely associated with POAG among those reporting a family history of glaucoma, particularly in relation to POAG with elevated IOP (P for trend = 0.0009; P interaction = 0.04). CONCLUSIONS: Overall caffeine intake was not associated with increased risk of POAG. However, in secondary analyses, caffeine appeared to elevate risk of high-tension POAG among those with a family history of glaucoma. This result may be due to chance, but warrants further study.
PURPOSE: To investigate whether caffeine, which transiently increases intraocular pressure (IOP) is associated with the risk of primary open-angle glaucoma (POAG). METHODS: A total of 79,120 women from 1980 to 2004 and 42,052 men from 1986 to 2004, who were 40+ years of age, did not have POAG, and reported undergoing eye examinations, were observed. Information on caffeine consumption, potential confounders, and POAG diagnoses were repeatedly updated in validated follow-up questionnaires. One thousand eleven incident POAG cases were confirmed with medical record review. Cohort-specific and pooled analyses across cohorts were conducted to calculate multivariate rate ratios (RRs). RESULTS: Compared with daily intake of less than 150 mg, the pooled multivariate RRs were 1.05 (95% confidence interval [CI], 0.89-1.25) for consumption of 150 to 299 mg/d, 1.19 (95% CI, 0.99-1.43) for 300 to 449 mg/d, 1.13 (95% CI, 0.89-1.43) for 450 to 559 mg/d, and 1.17 (95% CI, 0.90-1.53) for 600+ mg/d (P for trend = 0.11). However, for consumption of five or more cups of caffeinated coffee daily, the RR was 1.61 (95% CI, 1.00-2.59; P for trend = 0.02); tea or caffeinated cola intake were not associated with risk. Greater caffeine intake was more adversely associated with POAG among those reporting a family history of glaucoma, particularly in relation to POAG with elevated IOP (P for trend = 0.0009; P interaction = 0.04). CONCLUSIONS: Overall caffeine intake was not associated with increased risk of POAG. However, in secondary analyses, caffeine appeared to elevate risk of high-tension POAG among those with a family history of glaucoma. This result may be due to chance, but warrants further study.
Authors: Mae O Gordon; Julia A Beiser; James D Brandt; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Michael A Kass Journal: Arch Ophthalmol Date: 2002-06
Authors: Jae H Kang; Stephanie J Loomis; Bernard A Rosner; Janey L Wiggs; Louis R Pasquale Journal: Invest Ophthalmol Vis Sci Date: 2015-04 Impact factor: 4.799
Authors: A Z Jiwani; D J Rhee; S C Brauner; M F Gardiner; T C Chen; L Q Shen; S H Chen; C L Grosskreutz; K K Chang; C E Kloek; S H Greenstein; S Borboli-Gerogiannis; D L Pasquale; S Chaudhry; S Loomis; J L Wiggs; L R Pasquale; A V Turalba Journal: Eye (Lond) Date: 2012-06-08 Impact factor: 3.775
Authors: Bao Jian Fan; Dan Yi Wang; Louis R Pasquale; Jonathan L Haines; Janey L Wiggs Journal: Invest Ophthalmol Vis Sci Date: 2011-03-28 Impact factor: 4.799